Oligonucleotides

• 

  Subject Areas on Research

  • 5'-3'-UTR interactions regulate p53 mRNA translation and provide a target for modulating p53 induction after DNA damage. 
  • A 'Semi-Protected Oligonucleotide Recombination' Assay for DNA Mismatch Repair in vivo Suggests Different Modes of Repair for Lagging Strand Mismatches. 
  • A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. 
  • A functional analysis of the spacer of V(D)J recombination signal sequences. 
  • A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action. 
  • A pressure-mediated nonviral method for efficient arterial gene and oligonucleotide transfer. 
  • A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial. 
  • A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor. 
  • Activation of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-cell acute lymphoblastic leukemia by remote 3'-BCL11B enhancers and coregulation by PU.1 and HMGA1. 
  • Acute suppression of insulin resistance-associated hepatic miR-29 in vivo improves glycemic control in adult mice. 
  • An endogenous TNF-alpha antagonist induced by splice-switching oligonucleotides reduces inflammation in hepatitis and arthritis mouse models. 
  • Anti-c-myc DNA increases differentiation and decreases colony formation by HL-60 cells. 
  • Anti-gene padlocks eliminate Escherichia coli based on their genotype. 
  • Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. 
  • Antidote-mediated control of an anticoagulant aptamer in vivo. 
  • Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay. 
  • Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). 
  • Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells. 
  • Aptamers: an emerging class of therapeutics. 
  • Atherothrombotic disorders: new insights from hematology. 
  • Basic matrices for the matrix-assisted laser desorption/ionization mass spectrometry of proteins and oligonucleotides. 
  • Binding specificity of a monoclonal anti-DNA antibody. 
  • Characterization of a cDNA for the unexpressed form of cytochrome P-450g from the (-g) rat and differentiation of its mRNA from that of the (+g) phenotype using specific oligoprobes. 
  • Characterization of the human Snrpn minimal promoter and cis elements within it. 
  • Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. 
  • Covalent protein-oligonucleotide conjugates by copper-free click reaction. 
  • Crystallization and preliminary crystallographic studies of the decadeoxyoligonucleotide d(CpGpTpApCpGpTpApCpG). 
  • Cyclic AMP mediated GSTP1 gene activation in tumor cells involves the interaction of activated CREB-1 with the GSTP1 CRE: a novel mechanism of cellular GSTP1 gene regulation. 
  • Cyclophilin A is localized to the nucleus and controls meiosis in Saccharomyces cerevisiae. 
  • Cysteine-tailed class I-binding peptides bind to CpG adjuvant and enhance primary CTL responses. 
  • DNA-binding protein RAP1 stimulates meiotic recombination at the HIS4 locus in yeast. 
  • Determination of estrogen receptor messenger ribonucleic acid (mRNA) and cytochrome P450 aromatase mRNA levels in adipocytes and adipose stromal cells by competitive polymerase chain reaction amplification. 
  • Determining stoichiometry in homomultimeric nucleic acid complexes using magnetic field induced residual dipolar couplings. 
  • Developing aptamers into therapeutics. 
  • Development of universal antidotes to control aptamer activity. 
  • Differential induction of 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase genes in Arabidopsis thaliana by wounding and pathogenic attack. 
  • Differential specificities and simultaneous occupancy of human MutSalpha nucleotide binding sites. 
  • Differentially labeled mutant oligonucleotides for analysis of protein-DNA interactions. 
  • Direct evidence for (G)O6···H2-N4(C)+ hydrogen bonding in transient G(syn)-C+ and G(syn)-m5C+ Hoogsteen base pairs in duplex DNA from cytosine amino nitrogen off-resonance R1ρ relaxation dispersion measurements. 
  • Domain structure and DNA binding regions of beta protein from bacteriophage lambda. 
  • Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design. 
  • Dr(a-) polymorphism of decay accelerating factor. Biochemical, functional, and molecular characterization and production of allele-specific transfectants. 
  • Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results. 
  • Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. 
  • Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study. 
  • Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. 
  • Egr-1 is activated by 17beta-estradiol in MCF-7 cells by mitogen-activated protein kinase-dependent phosphorylation of ELK-1. 
  • Endothelial healing in vein grafts: proliferative burst unimpaired by genetic therapy of neointimal disease. 
  • Enhanced Sensitivity for Detection of HIV-1 p24 Antigen by a Novel Nuclease-Linked Fluorescence Oligonucleotide Assay. 
  • Enhancing immunogenicity by CpG DNA. 
  • Enzymatic fabrication of DNA nanostructures: extension of a self-assembled oligonucleotide monolayer on gold arrays. 
  • Enzymatic nanolithography of a self-assembled oligonucleotide monolayer on gold. 
  • Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. 
  • Exploring molecular diversity with combinatorial shape libraries. 
  • Expression of a candidate sex-determining gene during mouse testis differentiation. 
  • Expression of normal and novel glucokinase mRNAs in anterior pituitary and islet cells. 
  • Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. 
  • Female steroid hormones use signal transducers and activators of transcription protein-mediated pathways to modulate the expression of T-bet in epithelial cells: a mechanism for local immune regulation in the human reproductive tract. 
  • First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. 
  • First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. 
  • Flexible use of high-density oligonucleotide arrays for single-nucleotide polymorphism discovery and validation. 
  • Gene therapy for human bypass grafts. 
  • Gene therapy with an E2F transcription factor decoy inhibits cell cycle progression in rat anti-Thy 1 glomerulonephritis. 
  • Identification of an essential site for transcriptional activation within the human T-cell receptor delta enhancer. 
  • Identification, cloning, and expression of a cytosolic megakaryocyte protein-tyrosine-phosphatase with sequence homology to cytoskeletal protein 4.1. 
  • Immune modulatory oligonucleotides in prevention of nasal allergen-induced Eustachian tube dysfunction in rats. 
  • Immune modulatory oligonucleotides in the prevention and treatment of OVA-induced eustachian tube dysfunction in rats. 
  • In vitro selection of aptamers from RNA libraries. 
  • In vivo selection of tumor-targeting RNA motifs. 
  • In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry. 
  • Incorporation of ribonucleoside 5'-(alpha-P-borano)triphosphates into a 20-mer RNA by T7 RNA polymerase. 
  • Infectious pathogen detection arrays: viral detection in cell lines and postmortem brain tissue. 
  • Influence of backbone chemistry on immune activation by synthetic oligonucleotides. 
  • Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons. 
  • Inhibition of murine macrophage IL-12 production by natural and synthetic DNA. 
  • Inhibition of murine macrophage nitric oxide production by synthetic oligonucleotides. 
  • Isolation and characterization of effector-loop mutants of CDC42 in yeast. 
  • Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy. 
  • Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. 
  • MicroRNA-122 associates with serum apolipoprotein B but not liver fibrosis markers in CHC genotype 1 infection. 
  • MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice. 
  • Mismatch-containing oligonucleotide duplexes bound by the E. coli mutS-encoded protein. 
  • Modulation of Hoogsteen dynamics on DNA recognition. 
  • Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. 
  • Multiplex detection of disease biomarkers using SERS molecular sentinel-on-chip. 
  • Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. 
  • Mutagenic effects of abasic and oxidized abasic lesions in Saccharomyces cerevisiae. 
  • Mutational analysis of a type II topoisomerase cleavage site: distinct requirements for enzyme and inhibitors. 
  • NPAS3 is a trachealess homolog critical for lung development and homeostasis. 
  • Novel delivery of oligonucleotides using a topical hydrogel tissue sealant in a murine partial nephrectomy model. 
  • Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application. 
  • Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. 
  • OligoCalc: an online oligonucleotide properties calculator. 
  • Oligonucleotide transformation of yeast reveals mismatch repair complexes to be differentially active on DNA replication strands. 
  • Oncogenic activation of c-ABL by mutation within its last exon. 
  • Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. 
  • Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia. 
  • Physical and chemical characterization of purified ovalbumin messenger RNA. 
  • Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels. 
  • Probing the DNA sequence specificity of Escherichia coli RECA protein. 
  • Protein fabrication automation. 
  • Protein phosphatase 5 is required for ATR-mediated checkpoint activation. 
  • Protein-binding oligonucleotides: the next frontier in antithrombotic therapy. 
  • REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis. 
  • RNA as an RNA polymerase: net elongation of an RNA primer catalyzed by the Tetrahymena ribozyme. 
  • RNA editing generates tissue-specific sodium channels with distinct gating properties. 
  • RNA-targeted therapeutics in cardiovascular disease: the time is now. 
  • RNase H activation by stereoregular boranophosphate oligonucleotide. 
  • Rapid identification of kidney cyst mutations by whole exome sequencing in zebrafish. 
  • Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor. 
  • Reaper is regulated by IAP-mediated ubiquitination. 
  • Requirement for Abl kinases in T cell receptor signaling. 
  • Ribozyme cleavage of a 2,5-phosphodiester linkage: mechanism and a restricted divalent metal-ion requirement. 
  • Role of nucleobase energetics and nucleobase interactions in single-stranded peptide nucleic acid charge transfer. 
  • Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). 
  • Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial. 
  • Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. 
  • Self-assembly of monodisperse oligonucleotide-elastin block copolymers into stars and compound micelles. 
  • Serum biomarkers associated with baseline clinical severity in young steroid-naïve Duchenne muscular dystrophy boys. 
  • Simultaneous genotyping and species identification using hybridization pattern recognition analysis of generic Mycobacterium DNA arrays. 
  • Something old, something new. 
  • Sp and GATA factors are critical for Apolipoprotein AI downstream enhancer activity in human HepG2 cells. 
  • Specificity analysis of monoclonal anti-DNA antibodies from B6-lpr/lpr mice. 
  • Structure of a tethered cationic 3-aminopropyl chain incorporated into an oligodeoxynucleotide: evidence for 3'-orientation in the major groove accompanied by DNA bending. 
  • Studies on base-boronated oligonucleotides. 2 (1). Incompatibility of DMT and cyanoborane groups during oligonucleotide synthesis. 
  • Successful Combination of Neuraxial and Regional Anesthesia in a Child With Advanced Spinal Muscular Atrophy Type 1 Receiving Maintenance Nusinersen Therapy: A Case Report. 
  • Surface-initiated enzymatic polymerization of DNA. 
  • Surface-to-surface bridges formed by reversibly assembled polymers. 
  • Synthesis of 5-(1-propynyl)-2'-deoxyuridine 5'-(alpha-P-borano)triphosphate and kinetic characterization as a substrate for mmlv reverse transcriptase. 
  • Synthesis of oligonucleoside boranophosphates via an H-phosphonate method without nucleobase protection. 
  • TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. 
  • The N2-ethylguanine and the O6-ethyl- and O6-methylguanine lesions in DNA: contrasting responses from the "bypass" DNA polymerase eta and the replicative DNA polymerase alpha. 
  • The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics. 
  • The effect of a single boranophosphate substitution with defined configuration on the thermal stability and conformation of a DNA duplex. 
  • The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors. 
  • The evolution of platelet-directed pharmacotherapy. 
  • The human T-cell leukemia virus-1 transcriptional activator Tax enhances cAMP-responsive element-binding protein (CREB) binding activity through interactions with the DNA minor groove. 
  • The induction of HMGB1 release from RAW 264.7 cells by transfected DNA. 
  • The influence of DNA sequence on the immunostimulatory properties of plasmid DNA vectors. 
  • The influence of base sequence on the immunological properties of defined oligonucleotides. 
  • The molecular basis of class II MHC allelic control of T cell responses. 
  • The molecular defect in type IIB von Willebrand disease. Identification of four potential missense mutations within the putative GpIb binding domain. 
  • The oncogenic microRNA miR-21 promotes regulated necrosis in mice. 
  • The potential of aptamers as anticoagulants. 
  • The receptor kinase family: primary structure of rhodopsin kinase reveals similarities to the beta-adrenergic receptor kinase. 
  • The role of the macrophage scavenger receptor in immune stimulation by bacterial DNA and synthetic oligonucleotides. 
  • Therapeutic aptamers and antidotes: a novel approach to safer drug design. 
  • Therapy and clinical trials. 
  • Tissue-specific transcription of the rat tyrosine hydroxylase gene requires synergy between an AP-1 motif and an overlapping E box-containing dyad. 
  • Transcription factor decoy to study the molecular mechanism of negative regulation of renin gene expression in the liver in vivo. 
  • Treatment of HCV infection by targeting microRNA. 
  • Vein graft preservation solutions, patency, and outcomes after coronary artery bypass graft surgery: follow-up from the PREVENT IV randomized clinical trial. 
  • Versatility of borane nucleic acids mimics for coding, decoding and modulating genetic information. 
  • [Localization of binding sites of E. coli DNA-dependent RNA-polymerase with photosensitive template analogs]. 
  • p38 MAPK is essential for secondary axis specification and patterning in sea urchin embryos. 
  • siRNA-based approaches in cancer therapy. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology